U.S. Markets closed

Keryx Biopharmaceuticals, Inc. (KERX)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
7.07-0.10 (-1.39%)
At close: 4:00PM EDT

7.07 0.00 (0.00%)
After hours: 6:12PM EDT

People also watch
  • 2Q17 earning announcement is 10 days earlier than the usual of last few quarters. I think it should be good news by KERX.
  • July Calls at 7's, 8's, 9's, and 10's zeroed out for tomorrow's expiration like a Swiss watch. Another month, another million skimmed and into the bank. Rinse repeat.
  • Phony bear raid this C.C. will be huge!!!!!
  • Kerx will be at 18 by the end of the year. Longs need to relax and stop giving their shares to these thieves. Insiders and Institutions have almost 90% of shares so settle down please.
  • shorts tried this same tactic before last quarter's C.C. they knocked the PPS down to $5.50 next day at C.C. it was $6.50 same thing here from $7 back to $8.50 this time...imo
  • now is the time to load up and take advantage of this bear raid......stellar earnings next thursday!!!!! imo
  • From dough on Twitter. Cowen $KERX 2Q17 US Auryxia sales estimate of $14.0MM is slightly above consensus of $12.9MM
  • Time for Longs to load up the truck and thank the shorts for playing with themselves all day. PPS of $18 by November and then $28 buyout in 2018.
  • going down on very low volume. sounds a buyers strike instead of a sellers deluge. I've never seen a stock have so many 100 share trades. Also Schwab says the stock is very hard to borrow.
  • can't help myself keep adding. Can't believe the weak hands.
  • How low do we go this time around? Fresenius and 4th of July scripts numbers scared potential buyers. For shorts it would be ideal timing for a bear raid - hope we don't get one this week.
  • I want to strangle someone. Just don't know who.
  • Whats up ? Are sales disappointing ? This has been a rough week......
  • Keryx Biopharmaceuticals to Host Conference Call of Second Quarter 2017 Financial Results on Thursday, July 27, 2017
  • same old same old with this stock. Creep up and bleed down ....... creep up and bleed down....
  • Options week . Will see this reds
  • Today's press release mentions the European approval back in 2015. I wonder if they'll be news on that front come conference call.
  • Last month we got generic Renvela as suspension; minus 8% and then a run to 8$
    Now the indian company cleared generic Renvela as tablet


    Probably the reason for the enthusiasm of the shorts

    Aurobindo shares leap with FDA approval for key drug
    Markets were anticipating the approval for Sevelamer as it is one of the complex generic drug.
  • Anyone trading this one using chart. Make sense to me the short set this up following the chart. And together with option week, make it a perfect timing to sell or short.
  • It sucks to be owner of this stock. Got abused from all directions. Nasdaq is at all time high and we are 6% down for whatever it is :( %#¥